BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

IDM S.A. 

172, rue de Charonne

Paris    75545  France
Phone: 33-0-1-40-09-04-11 Fax: 33-0-1-40-09-04-25


SEARCH JOBS




Collaborations

Medarex, Inc.  Broad HuMAb-Mouse antibody development agreement and Anti-CTLA-4 cancer vaccine development.





 Company News
Epimmune Inc. (EPMN) And IDM S.A. Agree To Combine Businesses 10/19/2005 5:13:01 PM    More...
Immuno-Designed Molecules Signs An R&D Agreement On Anti-Cancer Vaccine With The Walter Reed Army Institute of Research 10/19/2005 5:12:06 PM    More...
IDM Seeking EUR92 Million In IPO To Fund Programs In Cancer 10/19/2005 5:11:43 PM    More...
French Biotech Firm Immuno-Designed Molecules Eyes 99 Millon Euro ($120.7 Million) IPO 10/19/2005 5:11:34 PM    More...
Immuno-Designed Molecules Launches A New Phase II/III Trial In Bladder Cancer 10/19/2005 5:10:34 PM    More...
IDM S.A. Will Present Phase II Trial Results For Its Melanoma Cancer Vaccine, Uvidem, At American Society of Clinical Oncology - Orlando - On May 15, 2005 10/19/2005 5:10:30 PM    More...
IDM, Inc. Announces Detailed Phase III Results For Mepact In Osteosarcoma To Be Presented At ASPHO Annual Meeting 10/19/2005 5:10:20 PM    More...
Kerry Segal Appointed Vice President, Business Development, At Immuno-Designed Molecules 10/19/2005 5:10:15 PM    More...
Epimmune Inc. (EPMN) Stockholders To Vote On Proposed IDM S.A. Business Combination At Annual Meeting Of Stockholders 10/19/2005 5:09:24 PM    More...
IDM And Cambridge Laboratories Limited Sign An Exclusive Marketing Agreement For Junovan(TM) (Mepact) In The United Kingdom And Ireland 10/19/2005 5:09:19 PM    More...
12

//-->